Role for intracellular proteases in the processing and transport of class II HLA antigens.
about
Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndromeCell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalizationMajor histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin LInvariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigensConformational lability in the class II MHC 310 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchangeThe invariant chain is required for intracellular transport and function of major histocompatibility complex class II moleculesDefective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expressionCathepsin S inhibitor prevents autoantigen presentation and autoimmunityStructural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide bindingEndosomal aspartic proteinases are required for invariant-chain processingA role for calnexin (IP90) in the assembly of class II MHC moleculesThe segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptidesDecreased endosomal delivery of major histocompatibility complex class II-invariant chain complexes in dynamin-deficient cellsInvariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sitesEvolution of the mammalian MHC: natural selection, recombination, and convergent evolution.Diminished intracellular invariant chain expression after vaccinia virus infection.Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design.Mtv-1 superantigen trafficks independently of major histocompatibility complex class II directly to the B-cell surface by the exocytic pathway.Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41.The cytoplasmic tail of invariant chain regulates endosome fusion and morphologyMouse B lymphocyte specific endocytosis and recycling of MHC class II moleculesStable surface expression of invariant chain prevents peptide presentation by HLA-DR.Neuronal loss and brain atrophy in mice lacking cathepsins B and LPulse-chase analysis for studies of MHC class II biosynthesis, maturation, and peptide loading.MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases.HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.Tripping on acid: trans-kingdom perspectives on biological acids in immunity and pathogenesis.HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation.DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potencyProcessing and presentation of an antigen of Mycobacterium avium require access to an acidified compartment with active proteases.Exit of major histocompatibility complex class II-invariant chain p35 complexes from the endoplasmic reticulum is modulated by phosphorylation.The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules.Assembly and peptide binding of major histocompatibility complex class II heterodimers in an in vitro translation system.Efficient endosomal localization of major histocompatibility complex class II-invariant chain complexes requires multimerization of the invariant chain targeting sequence.Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartmentsAggregation as a determinant of protein fate in post-Golgi compartments: role of the luminal domain of furin in lysosomal targetingIi chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes.
P2860
Q24320302-08177C91-A1E4-4499-8B5C-954E22402839Q24561527-AE249D81-2934-4075-81CD-B87D16227889Q24678337-CE399FD6-CA86-4747-B251-899B062D6406Q24678747-383C53D9-EEEF-4D9E-BD40-F0C4D2BA52E1Q27675571-C99560E9-73A1-4558-9E6D-90B0DB364CFCQ28585584-A456BF75-A973-4814-B7B7-FDB094917398Q28585705-302A156A-4445-4D6E-92BE-00648D8DB32FQ28591251-40157854-BE31-442C-A2C1-B5EEE483C5FCQ28612873-97337ED5-1BE5-4852-85BE-AFAD54B01E12Q28612976-5AE47F5D-07FF-4DAF-8B27-1287F3E89B45Q28613001-A696385C-8045-43D4-9ABC-8CBC475EF3F0Q28613064-BDBAA525-0F2C-45EE-A912-4FDAAE104E13Q28613183-97C6AA64-9C2F-4374-9E09-43B2DEE2C422Q28776057-6211F69B-293A-4C6E-99C9-4553F9D9F412Q33535951-CD3CC392-43FC-4D3D-A2AA-430E3747F722Q33614461-61F078C1-F080-4EE3-89D6-105C9042283DQ33630613-3DECF6E9-CCB4-4C5E-B551-E7B4C079E726Q33747640-CFE22F78-B84D-48DE-931F-A970DC9AA768Q33765990-54C2D880-DCF0-42F7-8B88-9E21CE9CDA8FQ33782440-D62540AD-505C-46AF-BFF4-CBE357141BCFQ33782938-9762E1C8-95F1-4A99-B863-16C3D7840DCCQ33829941-25BA12EC-5ACF-4CFC-9974-848FDC2A200FQ33898764-ECB972AC-2186-4822-AF65-C28796B2EBBBQ33922460-0176E662-A410-47C4-9617-195E2309D325Q33938149-D1DE501D-A20C-4B99-AC72-7272E5E62C24Q34030250-291FDA45-B642-4F67-879A-F630A4EBFDDFQ34155809-A4A86395-6235-4548-ADCB-FF30B8F11798Q34299840-4345FB64-B300-42E8-A70C-E8EB45CDCB2AQ34483195-BC124342-9419-4135-9F1B-63F73AA4793CQ34845436-7B889DF2-3815-4E16-AA5D-3EE0B023224BQ34948997-9A7804C4-BE89-4EF9-A602-F3238A442D1EQ35210348-334CCA98-0814-48EA-9DAE-F8B733F708A2Q35523431-F7231558-ADF2-4741-9A23-6FBF5013083FQ35788191-D3216EB7-5850-43D4-94BA-868FD4ACEB81Q35821240-49A5A615-C526-49B9-A154-CBEFCE62566EQ35857485-91668667-D838-4D77-B712-C52B50FF1B1EQ36235619-E7CD80E0-C768-404C-999A-AAB969DDE666Q36236708-1B232DED-D2FF-467A-80F2-E49DD1488B1DQ36255053-F268BD88-90FF-4D46-A3A1-C1F3D9EA1463Q36274077-BDF1F38F-53E4-47CE-A4F8-20DFE8EDBC57
P2860
Role for intracellular proteases in the processing and transport of class II HLA antigens.
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Role for intracellular proteas ...... port of class II HLA antigens.
@ast
Role for intracellular proteas ...... port of class II HLA antigens.
@en
Role for intracellular proteas ...... port of class II HLA antigens.
@nl
type
label
Role for intracellular proteas ...... port of class II HLA antigens.
@ast
Role for intracellular proteas ...... port of class II HLA antigens.
@en
Role for intracellular proteas ...... port of class II HLA antigens.
@nl
prefLabel
Role for intracellular proteas ...... port of class II HLA antigens.
@ast
Role for intracellular proteas ...... port of class II HLA antigens.
@en
Role for intracellular proteas ...... port of class II HLA antigens.
@nl
P2860
P356
P1476
Role for intracellular proteas ...... port of class II HLA antigens.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.11.3975
P407
P577
1988-06-01T00:00:00Z